Core Points - Evaxion A/S, a clinical-stage TechBio company, will provide a business update and report its Q3 2025 financial results on November 6, 2025 [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in developing AI-Immunology™ powered vaccines, focusing on immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and develop novel immunotherapies [4] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]

Core Insights - Evaxion A/S is set to provide a business update and report its Q3 2025 financial results on October 31, 2025, before the Nasdaq CM opens [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in AI-Immunology™ powered vaccines, focusing on developing novel immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S is a pioneering TechBio company utilizing its AI platform, AI-Immunology™, to decode the human immune system [4] - The company has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]

Financial Position - Evaxion A/S has raised a total of $7.2 million recently, with $4.5 million from an at-the-market offering and $2.7 million from the exercise of investor warrants [2][7] - The company now has sufficient cash to fund its operations and R&D programs into the second half of 2027, extending from the first half of 2027 [1][7] Debt Management - By the end of the second quarter of 2025, Evaxion had cash on hand of $14.7 million and a debt of $9.2 million [4] - The debt was reduced by $4.1 million through a debt-to-equity conversion agreement with the European Investment Bank in July 2025, enhancing the company's equity position [4] Operational Insights - Evaxion expects to incur an operational cash spend of $14 million in 2025 [4] - The recent exercises of investor warrants have decreased the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 million, leaving a total of 2.8 million outstanding warrants [3][7] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [5] - The company is focused on creating novel personalized vaccines and has a pipeline addressing high unmet medical needs in infectious diseases [5]

Core Viewpoint - Evaxion A/S has appointed Dr. Helen Tayton-Martin as the new CEO, effective November 24, 2025, marking a significant leadership change for the company as it continues to develop its AI-Immunology™ powered vaccines [1][4]. Company Leadership - Dr. Helen Tayton-Martin holds a Ph.D. in molecular immunology and an MBA from London Business School, with extensive experience in the biotech sector, including co-founding Adaptimmune and overseeing its growth and strategic partnerships [2][9]. - Birgitte Rønø, who served as interim CEO, will return to her role as Chief Scientific Officer, continuing to lead research and development efforts [5][9]. Board Changes - Dr. Tayton-Martin will step down from Evaxion's Board of Directors upon assuming the CEO role, while Jens Bitsch-Norhave will join the Board as an adviser and observer, with plans to seek election as a board member in 2026 [7][8]. Company Strategy and Potential - Dr. Tayton-Martin expressed excitement about joining Evaxion at a pivotal time, highlighting the company's AI-Immunology platform and recent achievements, such as the out-licensing of EVX-B3 to MSD and promising data for EVX-01 presented at ESMO [6][9]. - Evaxion is focused on developing novel immunotherapies for cancer and infectious diseases, leveraging its AI technology to address high unmet medical needs [11].

Group 1 - Evaxion (NASDAQ:EVAX) is identified as a promising investment opportunity with significant upside potential, highlighted by an increase in price target from $6 to $11 by Lake Street analyst Thomas Flaten, who maintains a Buy rating on the shares [1][2] - The recent announcement of two-year Phase 2 data for Evaxion's personalized cancer vaccine, EVX-01, in advanced melanoma has contributed to this positive sentiment, indicating the vaccine's potential in treating multiple advanced solid cancers [2] - EVX-01 is recognized as Evaxion's lead clinical asset, and the positive data not only supports the efficacy of the vaccine but also validates Evaxion's overall platform, especially in light of Merck & Co. Inc.'s option exercise for EVX-B3 [2][3] Group 2 - Evaxion is a clinical-stage biotech company focused on developing AI-powered immunology vaccines, previously known as Evaxion Biotech until its name change in May 2025 [3] - Merck & Co. Inc. is a key player in the healthcare sector, providing a range of products including human health pharmaceuticals, veterinary pharmaceuticals, and vaccines [3]

Core Insights - The webinar focuses on the 2-year readout from Evaxion's Phase II study in advanced melanoma, highlighting the significance of the results and their implications for high-risk melanoma treatment [1][2]. Group 1: Company Overview - Evaxion is introducing its AI-Immunology platform, which is central to its research and development efforts in advanced melanoma [2]. Group 2: Study Details - The agenda includes an introduction to Evaxion, a review of data from the Phase I study that led to the Phase II study, and a detailed presentation of the Phase II study design and results by Professor Khattak [2]. - The Phase II study results are expected to provide insights into the effectiveness of the treatment for high-risk melanoma patients [1][2]. Group 3: Engagement and Interaction - The webinar encourages audience participation through a question-and-answer session, allowing attendees to engage directly with the presenters [2].

Summary of Evaxion Biotech A/S Update / Briefing (October 22, 2025) Company Overview - **Company**: Evaxion Biotech A/S - **Founded**: 2008 in Copenhagen, Denmark - **Focus**: AI-first company leveraging proprietary AI-Immunology platform for vaccine discovery, design, and development [3][4] Industry Context - **Disease Focus**: Advanced melanoma, a highly aggressive skin cancer with high mortality rates, particularly in metastatic cases [14][15] - **Historical Context**: Prior to 2011, melanoma clinical trials had a high failure rate. Introduction of immunotherapy marked a significant shift in treatment efficacy [14][15] Core Points from the Call AI-Immunology Platform - **Functionality**: Decodes human systems for therapeutic target discovery by integrating genomic, transcriptomic, and proteomic data [3][4] - **Success Rate**: High success in selecting targets that induce potent T-cell responses against cancer cells [4] Clinical Trials - **Phase 1 Trial**: - Conducted on patients with Stage 3B and Stage 4 melanoma. - **Results**: 67% objective response rate (ORR) with 8 out of 12 patients showing response; however, 7 relapsed [8][9] - **Safety**: Well tolerated with mainly grade one and two adverse events [7][8] - **Key Learnings**: Recommended Phase 2 dose set at 200 micrograms; booster administrations included in Phase 2 to sustain T-cell levels [8][9] - **Phase 2 Trial**: - Included treatment-naive patients with Stage 3 unresectable or Stage 4 melanoma [18][19] - **Primary Endpoint**: Conversion from stable disease to partial or complete response [19][20] - **Secondary Endpoints**: Objective response rate, progression-free survival, overall survival, and neoantigen-specific T-cell response [20] - **Study Population**: 17 enrolled patients, predominantly Stage 4 melanoma [23] - **Safety Profile**: Consistent with Phase 1, primarily grade one adverse events [24][25] - **Results**: 75% best objective response rate; 54% conversion rate from stable disease to partial response [30][31] Efficacy and Safety - **T-cell Responses**: 81% of neoantigens induced T-cell responses, an increase from 65% in Phase 1 [31] - **Sustained Responses**: 92% of responders maintained responses at the 24-month mark [37] - **Manufacturing Success**: 100% success rate in vaccine manufacturing for all patients [38] Additional Insights - **Personalized Treatment**: Emphasis on the need for personalized therapies to improve efficacy and reduce toxicity compared to standard treatments [17][18] - **Future Directions**: Potential for further studies to explore the efficacy of personalized vaccines in previously treated melanoma patients and the role of booster doses [68][70] Conclusion - **Encouraging Data**: The results from the Phase 2 trial support the ongoing development of Evaxion's personalized cancer vaccine, EVX-01, in high-risk melanoma [38] - **Next Steps**: Continued evaluation of patient responses and potential adjustments to dosing schedules and treatment regimens based on emerging data [62][63]

Core Insights - Evaxion A/S announced unprecedented two-year clinical efficacy data for its personalized cancer vaccine EVX-01 in patients with advanced melanoma, showcasing a significant potential as a new treatment option [1][6] Clinical Efficacy Data - The two-year phase 2 data revealed an Objective Response Rate (ORR) of 75%, with 12 out of 16 patients showing objective clinical responses, including four achieving complete response [2][11] - A durable clinical benefit was noted, with 92% of patients still responding at the 24-month follow-up and no relapses observed [2][11] - 54% of patients experienced a deepened response during treatment, transitioning from stable disease or partial response to partial or complete response [3][9] Immune Response and Safety - EVX-01 induced an immune response in all patients, with 81% of targeted neoantigens generating potent specific T-cell responses, indicating high immunogenicity [4][11] - The treatment was confirmed to be well-tolerated, aligning with the favorable safety profile observed in the phase 1 study [5][11] Future Developments - The trial has been extended for an additional year, during which participants will receive EVX-01 as monotherapy, with data from this extension expected to be presented in 2026 [14] - Evaxion plans to discuss the data with stakeholders and potential partners, emphasizing the need for partnerships in further clinical development [6][12] Presentation and Engagement - Data was presented at the European Society for Medical Oncology (ESMO) Congress 2025, with opportunities for discussions at the conference [8][11] - An online webinar featuring key opinion leader Professor Muhammad Adnan Khattak is scheduled for October 22, 2025, to discuss the two-year phase 2 data and challenges in treating advanced melanoma [12]

Core Insights - Evaxion Biotech A/S (NASDAQ:EVAX) has a target price of -0.34, which is 104.29% below its current market price of 7.84, indicating a pessimistic outlook from analysts [1][3][5] - TransCode Therapeutics, Inc. (RNAZ) has a current stock price of 14.28 and a target price of 16.21, suggesting a growth potential of 13.52%, positioning it as a more favorable investment opportunity compared to EVAX [2][4][5] Company Analysis - The significant gap between EVAX's target and market prices raises concerns about its future performance and may impact investor confidence [3][5] - RNAZ's positive target price change reflects confidence in its growth prospects, making it an attractive option for investors in the biotech sector [4][5]

Company Overview - Evaxion is pioneering AI-powered drug development, focusing on vaccines for cancer and infectious diseases[5] - The company leverages a clinically validated AI-Immunology platform for target discovery, design, and development[5, 26] - Evaxion aims to generate positive cash flow and become the AI partner of choice in the TechBio industry[13, 14] Financial Highlights - An exercise fee of $7.5 million from MSD extends Evaxion's cash runway to H1 2027[8, 17] - Evaxion has potential cash generation of up to $592 million over the coming two decades through the MSD partnership[8] - As of June 30, 2025, Evaxion has $14.7 million in cash and $9.2 million in debt[60] - The market capitalization of Evaxion is $29.3 million as of September 30, 2025[60] Pipeline and Partnerships - MSD acquired EVX-B3, validating Evaxion's AI-Immunology platform and pipeline[8] - The global cancer immunotherapy market is estimated to grow to $277 billion by 2030[11] - The infectious disease vaccines market is expected to reach $67.5 billion by 2031[11] - The melanoma market is estimated to grow to $7.4 billion by 2029[11]